Designing and Simulating the Structure of an Effective Immunotoxin in Breast Cancer

Maleknejadyazdi, Mona; Haddad-Mashadrizeh, Ali Akbar

doi:10.22034/pmj.2023.2015028.1018

Document Type : Original Article

Authors

¹ Biology Department, University Jihad Unit, University of Science and Arts of Yazd, Iran.

² Department of Molecular and Cell Biology, Institute of Biotechnology, and Department of Ferdowsi University of Mashhad, Iran.

https://doi.org/10.22034/pmj.2023.2015028.1018

Abstract

Immunotoxins have been used for cancer treatment. The immunotoxin binds to the surface antigen on the cancer cell, enters inside the cell by endocytosis1, and destroys the cancer cell. In addition, the components of this type of drug and assembly based on peptide bonds2, and the creation of recombinant protein construction were among the requirements investigated in this study. In this bioinformatics research, membrane antigen structural, and functional properties on the surface of breast cancer cells were investigated and evaluated to target cancer cells. An EGFR3 antigen with a shorter amino acid length for positive binding and INS4, which has 110 amino acids, binding +, and a binding score of 0.99, was selected as the most efficient ligand using the AAASGG 3 (GGGGS) linker5, resulting in a six-recombinant structure. Hence, the targeted treatment of cancer through immunotoxin with the confirmation of the patent sequence led to the creation of a recombinant structure, which was analyzed with bioinformatics software. To ensure accurate results in the laboratory, we utilized Escherichia coli strain DH5 as a host during the cloning phase for plasmid DNA replication. This enabled a more precise and reliable replication process, thereby confirming the validity of our computational modeling, and the results of this research led to the modeling and simulation of the engineering structure of Cetuximab ZZpe38 immunotoxin. For future research, gene expression in mammalian cells will be the focus.

Keywords

20.1001.1.24765538.2023.8.31.2.3

Main Subjects

Cell Therapy

References

1.Lanzarone G, Olivi M. The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina. 2021;57(8):813. [DOI: 10.3390/medicina57080813].

2.Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9.

3.Lasho T, Finke C, Hanson C, Jimma T, Knudson R, Ketterling R, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012;26(5):1135-7.

4.Killick SB, Wiseman DH, Quek L, Cargo C, Culligan D, Enright H, et al. British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes. British Journal of Haematology. 2021;194(2):282-93.

5.Grinfeld J, Nangalia J, Baxter E, Wedge D, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416-30.

6.Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology. 2021;34(1):20-31.

7.Bruneau J, Molina TJ. WHO classification of tumors of hematopoietic and lymphoid tissues. Hematopathology. 2020:501-5.

8.Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, The Journal of the American Society of Hematology. 2014;124(7):1062-9.

9.Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018;103(2):e63.

10.Scott LM. The JAK2 exon 12 mutations: a comprehensive review. American journal of hematology. 2011;86(8):668-76.

11.Wong R, Sun S, Wang H-Y, Broome HE, Murray S, Thorson J. In Frame Calr Exon 9 Mutations: Often Ignored but Potentially Significant. Blood. 2018;132:5480.

12.Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R. Clinical and laboratory features of JAK2 V617F, CALR, and MPL Mutations in Malaysian patients with classical myeloproliferative neoplasm (MPN). International journal of environmental research and public health. 2021;18(14):7582.

13.Heppner J, Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC research notes. 2019;12(1):1-5.

14.Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Journal of hematology & oncology. 2016;9(1):1-11.

15.Yassin MA, Taher A, Mathews V, Hou H-A, Shamsi T, Tuglular T, et al. Myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria: epidemiological indices and treatment practice patterns from the multinational, multicenter, observational MERGE registry. Blood. 2018;132:5461.

16.Ashorobi D, Gohari P. Essential thrombocytosis. StatPearls [Internet]. 2021.

17.Belcic Mikic T, Pajic T, Sever M. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Scientific reports. 2019;9(1):1-9.

18.Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Young Ok C, Salim AA, Routbort MJ, et al. Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American journal of clinical pathology. 2016;145(3):418-27.

19.Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, et al. The Prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1–negative myeloproliferative neoplasms. American journal of clinical pathology. 2015;144(1):165-71.

20.Kim BH, Cho Y-U, Bae M-H, Jang S, Seo E-J, Chi H-S, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. Journal of Korean medical science. 2015;30(7):882-8.

21.Lieu C-H, Shen Y-J, Lai W-C, Tsai W-H, Hsu H-C. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. Journal of the Chinese Medical Association. 2010;73(10):530-2.

22.Akpinar T, Hançer V, Nalçaci M, Diz-Küçükkaya R. Kronik miyeloproliferatif neoplazmlarda MPL W515L/K mutasyonlari. Turk J Hematol. 2013;30:8-12.

23.Shams SF, Ayatollahi H, Sadeghian MH, Afzalaghaee M, Shakeri S, Yazdandoust E, et al. Prevalence of MPL (W515K/L) mutations in patients with negative-JAK2 (V617F) myeloproliferative neoplasm in North-East of Iran. Iranian journal of pathology. 2018;13(4):397.

24.Rabade N, Subramanian P, Kodgule R, Raval G, Joshi S, Chaudhary S, et al. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian Journal of Pathology and Microbiology. 2018;61(2):209.

25.Xia D, Hasserjian RP. Molecular testing for JAK 2, MPL, and CALR in myeloproliferative neoplasms. American Journal of Hematology. 2016;91(12):1277-80.

Personalized Medicine Journal

Designing and Simulating the Structure of an Effective Immunotoxin in Breast Cancer

References

References

Volume 8, Issue 31
original article
December 2023
Pages 10-25

Designing and Simulating the Structure of an Effective Immunotoxin in Breast Cancer

References

References

Volume 8, Issue 31 original articleDecember 2023Pages 10-25

Volume 8, Issue 31
original article
December 2023
Pages 10-25